Chronic subdural hematoma (cSDH) is a common neurosurgical condition, especially in the elderly. Traditionally, it was thought to be a result of trauma leading to rupture of bridging veins, but this view is now being challenged. Emerging evidence points to a more complex pathophysiology involving a “vicious cycle” of inflammation, angiogenesis, and fibroproliferation. Damage to dural border cells initiates an inflammatory cascade that leads to membrane formation and the release of pro-inflammatory and pro-angiogenic factors. These processes result in fragile, leaky capillaries and recurrent micro-bleeds, perpetuating a cycle of hematoma growth and persistence. This evolving understanding shifts the focus from mechanical injury to dynamic biological processes, paving the way for novel treatments. This review addresses the anatomical substrate, molecular mechanisms, and functions of specific cytokines [i.e., interleukin (IL)-6, IL-1β] in cSDH development. From this evolving understanding of cSDH pathophysiology, various treatments are being developed to counteract these biological processes. In addition to traditional surgery like burr-hole drainage and endoscopic evaluation, pharmacologic interventions such as statins, corticosteroids have yielded encouraging results. Middle meningeal artery embolization (MMAE) is a novel minimally invasive procedure that breaks the inflammatory-angiogenic cycle at its core by devascularizing the dura. Randomized trials evaluating MMAE have consistently shown significant reductions in recurrence and MMAE is being integrated into treatment protocols for recurrent or refractory cSDH. In conclusion, cSDH should be viewed not as an inert hematoma but as an active, dynamic process. An integrated understanding of its pathophysiologic basis reveals new therapeutic opportunities for targeted, multimodal therapy to improve long-term outcome in this increasingly prevalent disorder.